US 11,865,090 B2
Tumor suppressive microRNAs for cancer therapy
Eithan Galun, Har Adar (IL); Hilla Giladi, Mevasseret Zion (IL); Chofit Chai, Nahariya (IL); Nofar Rosenberg, Modi'in (IL); Dayana Yaish, Jerusalem (IL); and Zohar Shmuelian, Ma'ale Adumim (IL)
Assigned to HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., Jerusalem (IL)
Appl. No. 16/977,722
Filed by Hadasit Medical Research Services and Development Ltd., Jerusalem (IL)
PCT Filed Mar. 6, 2019, PCT No. PCT/IL2019/050244
§ 371(c)(1), (2) Date Sep. 2, 2020,
PCT Pub. No. WO2019/171375, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/640,060, filed on Mar. 8, 2018.
Prior Publication US 2021/0052523 A1, Feb. 25, 2021
Int. Cl. C07H 21/02 (2006.01); A61K 31/167 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/167 (2013.01) [A61P 35/00 (2018.01); A61P 35/04 (2018.01)] 14 Claims
 
1. A method of treating hepatocellular carcinoma in a subject in need thereof, the method comprising administering to the subject a composition comprising a RORα agonist, selected from the group consisting of SR1078 and Lauric acid (LA), capable of increasing production or expression of one or more endogenous tumor suppressive miRNAs in one or more miRNA producing cells, wherein the one or more tumor suppressive endogenous miRNAs comprise miR-34a, such that the one or more endogenous tumor suppressive miRNAs affect one or more target hepatocellular carcinoma cells, thereby treating hepatocellular carcinoma in said subject.